4D pharma today announced it registered with the SEC to list on the Nasdaq under the symbol ‘LBPS’ following its proposed merger with Longevity Acquisition. The deal is expected to close in Q1 2021, pending shareholder approval. Shareholders earlier this week voted to grant the SPAC an extension until May 2021 to close a deal. Longevity has filed a preliminary proxy on the proposed combination. Read more.
Related Posts
RMG Files Amended Proxy on Romeo Merger Plan
RMG Acquisition set Dec. 28 for a shareholder vote on the SPAC's proposed combination with Romeo Systems, which manufactures litium-ion battery packs.
23andMe Calls all Outstanding Warrants
The redemption deadline for the one-third warrants is Dec. 22 at an exercise price of $11.50 a share for whole warrants.
26 Capital Acquisition Taps Sponsor for $4M Loan
The SPAC for more than a year and a half has been trying to move forward on a merger with Phillipines casino operator Okada Manila, now known as UE Resorts International. The deal values the casino operator at $2.6 billion.
Corner Growth Acquisition 2 Seeks Deadline Extension
The SPAC has said it expects to focus on the technology industry in the United States and other developed countries.